We are live on ! Find out more
BPMC

Blueprint Medicines
BPMC

Delisted

BPMC was delisted on the 17th of July, 2025.

Back to rankings

87 hedge funds and large institutions have $567M invested in Blueprint Medicines in 2016 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 29 increasing their positions, 27 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 12

44% more capital invested

Capital invested by funds: $395M → $567M (+$172M)

6% more funds holding

Funds holding: 82 → 87 (+5)

7% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 27

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

54% less call options, than puts

Call options by funds: $425K | Put options by funds: $921K

Holders
87
Holders Change
+5
Holders Change %
+6.1%
% of All Funds
2.32%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.11%
New
18
Increased
29
Reduced
27
Closed
12
Calls
$425K
Puts
$921K
Net Calls
-$496K
Net Calls Change
-$465K

Top Buyers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
+$20.3M
2
OM
Opaleye Management
Massachusetts
+$13.3M
3
PAMU
Pictet Asset Management (UK)
United Kingdom
+$7.6M
4
DM
Deerfield Management
New York
+$5.36M
5
CAM
Cormorant Asset Management
Massachusetts
+$4.91M

Top Sellers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
-$27.2M
2
PI
Putnam Investments
Massachusetts
-$9.68M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$6.01M
4
Fidelity International
Fidelity International
Bermuda
-$4.33M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.88M
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$4.89M +$132K +5,325 +3%
PI
27
Putnam Investments
Massachusetts
$2.93M -$9.68M -389,522 -80%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$2.55M +$377K +15,172 +21%
Charles Schwab
29
Charles Schwab
California
$2.36M +$884K +35,593 +81%
BIM
30
BlackRock Investment Management
Delaware
$2.3M +$8.25K +332 +0.4%
NC
31
NBW Capital
Massachusetts
$1.26M -$11.9K -478 -1%
Allianz Asset Management
32
Allianz Asset Management
Germany
$1.26M +$1.05M +42,430 New
California State Teachers Retirement System (CalSTRS)
33
California State Teachers Retirement System (CalSTRS)
California
$1.25M +$7.45K +300 +0.7%
Deutsche Bank
34
Deutsche Bank
Germany
$1.07M -$757K -30,485 -46%
TA
35
Teachers Advisors
New York
$952K – – –
Goldman Sachs
36
Goldman Sachs
New York
$940K +$786K +31,637 New
Swiss National Bank
37
Swiss National Bank
Switzerland
$897K – – –
RG
38
Redmile Group
California
$818K -$20.2K -814 -3%
AllianceBernstein
39
AllianceBernstein
Tennessee
$793K +$214K +8,600 +48%
SO
40
STRS Ohio
Ohio
$778K +$651K +26,200 New
D.E. Shaw & Co
41
D.E. Shaw & Co
New York
$688K +$575K +23,155 New
Millennium Management
42
Millennium Management
New York
$653K +$547K +22,003 New
New York State Common Retirement Fund
43
New York State Common Retirement Fund
New York
$609K – – –
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$591K +$91.2K +3,670 +23%
CS
45
Credit Suisse
Switzerland
$584K -$147K -5,918 -23%
Federated Hermes
46
Federated Hermes
Pennsylvania
$572K +$478K +19,262 New
ProShare Advisors
47
ProShare Advisors
Maryland
$570K -$88.1K -3,546 -16%
Citadel Advisors
48
Citadel Advisors
Florida
$554K +$463K +18,650 New
DC
49
Deere & Company
Illinois
$476K -$139K -5,612 -26%
MLICM
50
Metropolitan Life Insurance Company (MetLife)
New York
$462K – – –
1
2
3 4

BPMC Hedge Fund Activity: Q3 2016 in Review

87 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q3 2016, worth a combined $567M — up 44% from $395M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new BPMC positions and 12 closed out — a net gain of 6 holders — while 29 added to existing stakes and 27 trimmed.

The largest buyer was Victory Capital Management, opening a new position worth an estimated $20.3M. The largest seller was PFM Health Sciences, cutting an estimated $27.2M.

  • 87 institutional investors held Blueprint Medicines (BPMC) as of Q3 2016, up from 82 in Q2 2016.
  • Funds reported $567M of Blueprint Medicines stock for Q3 2016, up 44% quarter-over-quarter.
  • 18 funds opened new Blueprint Medicines positions in Q3 2016 and 12 closed out, a net change of +6 holders.
  • The largest Blueprint Medicines buyer in Q3 2016 was Victory Capital Management, an estimated $20.3M added.
  • The largest Blueprint Medicines seller in Q3 2016 was PFM Health Sciences, an estimated $27.2M sold.

Based on aggregated 13F filings for Q3 2016.